Agios Pharmaceuticals, Inc. engages in the discovery and development of medicines in the field of cellular metaboli® and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes. AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications.
Market Cap | 1.208 Billion | Shares Outstanding | 55.739 Million | Avg 30-day Volume | 677.462 Thousand |
P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | -1.64 |
Price to Revenue | 141.0767 | Debt to Equity | 0.0 | EBITDA | -383.925 Million |
Price to Book Value | 1.5574 | Operating Margin | -3926.2717000000002 | Enterprise Value | 508.751 Million |
Current Ratio | 12.056 | EPS Growth | -0.684 | Quick Ratio | 11.103 |
1 Yr BETA | 1.2394 | 52-week High/Low | 31.87 / 19.8 | Profit Margin | -3777.9571 |
Operating Cash Flow Growth | 11.5058 | Free Cash Flow to Firm (FCFF) TTM | -259.382 Million | Free Cash Flow to Equity (FCFE) TTM | |
Altman Z-Score | 5.3918 |
Please sign in first
none
none
none
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
JONES CECILIA CHIEF FINANCIAL OFFICER |
|
9,575 | 2023-09-26 | 3 |
BURNS JAMES WILLIAM CHIEF LEGAL OFFICER |
|
23,890 | 2023-08-17 | 6 |
|
2,302 | 2023-08-11 | 2 | |
|
2,302 | 2023-08-11 | 2 | |
|
13,724 | 2023-08-09 | 4 | |
GOFF BRIAN CHIEF EXECUTIVE OFFICER |
|
26,592 | 2023-08-08 | 3 |
WASHBURN THEODORE JAMES JR. PRINCIPAL ACCOUNTING OFFICER |
|
2,741 | 2023-08-07 | 7 |
GHEUENS SARAH CHIEF MEDICAL OFFICER |
|
0 | 2023-07-01 | 6 |
|
106,966 | 2023-06-28 | 4 | |
MILANOVA TSVETA CHIEF COMMERCIAL OFFICER |
|
3,831 | 2023-06-28 | 3 |
|
472,708 | 2023-06-21 | 9 | |
|
11,524 | 2023-06-21 | 2 | |
|
12,095 | 2023-06-21 | 2 | |
|
0 | 2023-06-13 | 2 | |
|
0 | 2023-06-13 | 2 | |
|
28,528 | 2022-12-31 | 1 | |
PODDAR RICHA CHIEF COMMERCIAL OFFICER |
|
18,501 | 2022-10-15 | 0 |
|
34,282 | 2022-06-21 | 0 | |
|
6,549 | 2022-05-20 | 0 | |
CAR BRUCE CHIEF SCIENTIFIC OFFICER |
|
52,500 | 2022-03-01 | 0 |
BILLER JONATHAN CHIEF FINANCIAL OFFICER |
|
57,116 | 2022-02-18 | 0 |
ALENSON CARMAN PRINCIPAL ACCOUNTING OFFICER |
|
3,555 | 2021-06-21 | 0 |
BOWDEN CHRISTOPHER CHIEF MEDICAL OFFICER |
|
16,479 | 2021-06-18 | 0 |
MILES DARRIN CHIEF COMMERCIAL OFFICER |
|
7,209 | 2021-05-14 | 0 |
HIRSCH ANDREW CHIEF FINANCIAL OFFICER |
|
24,272 | 2020-04-22 | 0 |
|
7,121,658 | 2019-11-12 | 0 | |
BILLER SCOTT CHIEF SCIENTIFIC OFFICER |
|
86,788 | 2019-06-11 | 0 |
HOERTER STEVEN L. CHIEF COMMERCIAL OFFICER |
|
10,941 | 2019-03-01 | 0 |
|
200,596 | 2017-12-06 | 0 | |
|
109,230 | 2017-03-03 | 0 | |
|
2,778 | 2016-08-10 | 0 | |
|
0 | 2016-06-21 | 0 | |
GODDARD GLENN SENIOR VICE PRESIDENT, FINANCE |
|
0 | 2016-02-16 | 0 |
HIGGONS JOHN DUNCAN CHIEF OPERATING OFFICER |
|
120,834 | 2016-01-04 | 0 |
|
0 | 2015-06-23 | 0 | |
|
184,386 | 2015-02-19 | 0 | |
ARCH VENTURE PARTNERS VII, L.P. |
|
No longer subject to file | 2015-02-19 | 0 |
|
No longer subject to file | 2015-02-19 | 0 | |
|
5,242,704 | 2014-12-16 | 0 | |
|
No longer subject to file | 2014-06-23 | 0 | |
|
5,014,059 | 2014-04-29 | 0 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
No current insider transactions |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|---|---|---|---|
AGIOS PHARMACEUTICALS INC AGIO | 2023-11-28 22:15:04 UTC | 4.9047 | 0.4153 | 2500000 |
AGIOS PHARMACEUTICALS INC AGIO | 2023-11-28 21:45:03 UTC | 4.9047 | 0.4153 | 2500000 |
AGIOS PHARMACEUTICALS INC AGIO | 2023-11-28 21:15:04 UTC | 4.9047 | 0.4153 | 2500000 |
AGIOS PHARMACEUTICALS INC AGIO | 2023-11-28 20:45:04 UTC | 4.9047 | 0.4153 | 2500000 |
AGIOS PHARMACEUTICALS INC AGIO | 2023-11-28 20:15:04 UTC | 4.9047 | 0.4153 | 2500000 |
AGIOS PHARMACEUTICALS INC AGIO | 2023-11-28 19:45:03 UTC | 4.9047 | 0.4153 | 2500000 |
AGIOS PHARMACEUTICALS INC AGIO | 2023-11-28 19:15:04 UTC | 4.9047 | 0.4153 | 2500000 |
AGIOS PHARMACEUTICALS INC AGIO | 2023-11-28 18:45:03 UTC | 4.9047 | 0.4153 | 2500000 |
AGIOS PHARMACEUTICALS INC AGIO | 2023-11-28 18:15:03 UTC | 4.9047 | 0.4153 | 2500000 |
AGIOS PHARMACEUTICALS INC AGIO | 2023-11-28 17:45:04 UTC | 4.9047 | 0.4153 | 2500000 |
AGIOS PHARMACEUTICALS INC AGIO | 2023-11-28 17:15:04 UTC | 4.9047 | 0.4153 | 2500000 |
AGIOS PHARMACEUTICALS INC AGIO | 2023-11-28 16:45:04 UTC | 4.9047 | 0.4153 | 2500000 |
AGIOS PHARMACEUTICALS INC AGIO | 2023-11-28 16:15:04 UTC | 4.9047 | 0.4153 | 2500000 |
AGIOS PHARMACEUTICALS INC AGIO | 2023-11-28 15:45:03 UTC | 4.9047 | 0.4153 | 2500000 |
AGIOS PHARMACEUTICALS INC AGIO | 2023-11-28 15:15:03 UTC | 4.9047 | 0.4153 | 2500000 |
AGIOS PHARMACEUTICALS INC AGIO | 2023-11-28 14:45:04 UTC | 4.9047 | 0.4153 | 2500000 |
AGIOS PHARMACEUTICALS INC AGIO | 2023-11-28 14:15:04 UTC | 4.9047 | 0.4153 | 2500000 |
AGIOS PHARMACEUTICALS INC AGIO | 2023-11-28 13:45:04 UTC | 4.9047 | 0.4153 | 2500000 |
AGIOS PHARMACEUTICALS INC AGIO | 2023-11-28 13:15:03 UTC | 4.9047 | 0.4153 | 2500000 |
AGIOS PHARMACEUTICALS INC AGIO | 2023-11-28 12:45:04 UTC | 4.9047 | 0.4153 | 2500000 |
Holder | Issuer | Net Short Position | Position Date | Origin |
---|---|---|---|---|
AGF Investments Trust- AGFIQ U.S. Market Neutral Value Fund | AGIO | -66.0 shares, $-2310.0 | 2020-09-30 | N-PORT |
AQR Funds- AQR Large Cap Relaxed Constraint Equity Fund | AGIO | -598.0 shares, $-19375.2 | 2019-09-30 | N-PORT |
FundVantage Trust- Gotham Master Neutral Fund | AGIO | -19.0 shares, $-665.0 | 2020-09-30 | N-PORT |
FundVantage Trust- Gotham Hedged Plus Fund | AGIO | -119.0 shares, $-3341.52 | 2022-12-30 | N-PORT |
Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund | AGIO | -2700.0 shares, $-66825.0 | 2023-09-30 | N-PORT |